Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine, Shanchol, in Haiti

PLoS Neglected Tropical Diseases

Volumn 8, Issue 5, 2014, Pages

  Charles, Richelle C ^a,b   Hilaire, Isabelle J ^c   Mayo Smith, Leslie M ^a   Teng, Jessica E ^c,d   Jerome, J Gregory ^c   Franke, Molly F ^b,c   Saha, Amit ^e   Yu, Yanan ^a   Kováč, Paul ^f   Calderwood, Stephen B ^a,b   Ryan, Edward T ^a,b,g   LaRocque, Regina C ^a,b   Almazor, Charles P ^c   Qadri, Firdausi ^e   Ivers, Louise C ^b,c,d   Harris, Jason B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS IN HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; O ANTIGEN; SHANCHOL; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; INACTIVATED VACCINE;

ADOLESCENT; ADULT; AGE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BANGLADESH; BLOOD GROUP; CHOLERA; COMPARATIVE STUDY; FEMALE; HAITI; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; SEROCONVERSION; VIBRIO CHOLERAE; BACTERIAL LOAD; BLOOD; CHILD; CLINICAL TRIAL; DRUG EFFECTS; EPIDEMIC; IMMUNOLOGY; INFANT; VIBRIO CHOLERAE O1; VIBRIO CHOLERAE O139; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; EPIDEMICS; FEMALE; HAITI; HUMANS; INFANT; MALE; VACCINES, INACTIVATED; VIBRIO CHOLERAE O1; VIBRIO CHOLERAE O139; YOUNG ADULT;

EID: 84901774350     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002828     Document Type: Article

References (39)

1. Ali M, Lopez AL, You YA, Kim YE, Sah B, et al. (2012) The global burden of cholera. Bull World Health Organ 90: 209-218A.
2. Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, et al. (2011) The origin of the Haitian cholera outbreak strain. N Engl J Med 364: 33-42.
3. Cravioto A, Lanata CF, Lantagne DS, Nair GB (2011) Final Report of the Independent Panel of Experts on the Cholera Outbreak in Haiti. 2011: 32. [updated May 4, 2011]. Available from: http://www.un.org/News/dh/infocus/haiti/UN-cholera-report-final.pdf.
4. Ministere de la Sante Publique et de la Population, (2013) Rapport de Cas 27 Novembre. 2013: 2013 Available from: http://www.mspp.gouv.ht/site/index.php?option=com_content&view=article&id=120&Itemid=1.
5. Ivers LC, Farmer P, Almazor CP, Leandre F, (2010) Five complementary interventions to slow cholera: Haiti. Lancet 376: 2048-2051.
6. Ryan ET, (2011) The cholera pandemic, still with us after half a century: time to rethink. PLoS Negl Trop Dis 5: e1003.
7. Sur D, Kanungo S, Sah B, Manna B, Ali M, et al. (2011) Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 5: e1289.
8. Kanungo S, Paisley A, Lopez AL, Bhattacharya M, Manna B, et al. (2009) Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 27: 6887-6893.
9. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, et al. (2009) Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374: 1694-1702.
10. Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, et al. (2013) 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 13: 1050-6.
11. WHO Publication (2010) Cholera vaccines: WHO position paper-Recommendations. Vaccine 28: 4687-4688.
12. Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, et al. (2013) Use of oral cholera vaccine in Haiti: a rural demonstration project. Am J Trop Med Hyg 89: 617-624.
13. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, et al. (2013) First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. PLoS Negl Trop Dis 7: e2465.
14. Ivers LC, Farmer PE, Pape WJ, (2012) Oral cholera vaccine and integrated cholera control in Haiti. Lancet 379: 2026-2028.
15. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, et al. (2005) Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366: 44-49.
16. Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, et al. (2011) Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29: 8285-8292.
17. Taylor DN, Cardenas V, Sanchez JL, Begue RE, Gilman R, et al. (2000) Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 181: 1667-1673.
18. Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, et al. (1986) Field trial of oral cholera vaccines in Bangladesh. Lancet 2: 124-127.
19. Kaper JB, Morris JG Jr, Levine MM, (1995) Cholera. Clin Microbiol Rev 8: 48-86.
20. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, et al. (1985) Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236-242.
21. Villeneuve S, Souchon H, Riottot MM, Mazie JC, Lei P, et al. (2000) Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc Natl Acad Sci U S A 97: 8433-8438.
22. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, et al. (2008) The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis 2: e173.
23. Leung DT, Uddin T, Xu P, Aktar A, Johnson RA, et al. (2013) Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol 20: 780-788.
24. Arifuzzaman M, Rashu R, Leung DT, Hosen MI, Bhuiyan TR, et al. (2012) Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera. Clin Vaccine Immunol 19: 1304-1311.
25. Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, et al. (2009) Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 77: 3850-3856.
26. Xu P, Alam MM, Kalsy A, Charles RC, Calderwood SB, et al. (2011) Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines. Bioconjug Chem 22: 2179-2185.
27. Karlsson EK, Harris JB, Tabrizi S, Rahman A, Shlyakhter I, et al. (2013) Natural selection in a Bangladeshi population from the cholera-endemic Ganges River Delta. Sci Transl Med 5: 192ra86.
28. [Anonymous] (2001) Cholera vaccines. Wkly Epidemiol Rec 76: 117-124.
29. Mosley WH, Benenson AS, Barui R, (1968) A serological survey for cholera antibodies in rural East Pakistan. 2. A comparison of antibody titres in the immunized and control population of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate. Bull World Health Organ 38: 335-346.
30. Jayasekera CR, Harris JB, Bhuiyan S, Chowdhury F, Khan AI, et al. (2008) Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J Infect Dis 198: 1055-1061.
31. Neoh SH, Rowley D, (1970) The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J Infect Dis 121: 505-513.
32. Majumdar AS, Ghose AC, (1981) Evaluation of the biological properties of different classes of human antibodies in relation to cholera. Infect Immun 32: 9-14.
33. Kuchta A, Rahman T, Sennott EL, Bhuyian TR, Uddin T, et al. (2011) Vibrio cholerae O1 infection induces proinflammatory CD4+ T-cell responses in blood and intestinal mucosa of infected humans. Clin Vaccine Immunol 18: 1371-1377.
34. Harris JB, Larocque RC, Chowdhury F, Khan AI, Logvinenko T, et al. (2008) Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2: e221.
35. Glass RI, Holmgren J, Haley CE, Khan MR, Svennerholm AM, et al. (1985) Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol 121: 791-796.
36. Chowdhury F, Khan AI, Harris JB, Larocque RC, Chowdhury MI, et al. (2008) A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. Pediatr Infect Dis J 27: 986-92.
37. Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, et al. (1989) ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis 159: 770-773.
38. Lagos R, Avendano A, Prado V, Horwitz I, Wasserman S, et al. (1995) Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun 63: 707-709.
39. Sack DA, Clemens JD, Huda S, Harris JR, Khan MR, et al. (1991) Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis 164: 407-411.